Genetic testing has expanded from a small set of targeted tests for specific known conditions to a range of approaches that can examine the genome at different levels of breadth and resolution. Among these, whole exome sequencing occupies a position that reflects a practical balance between the comprehensiveness of full genome sequencing and the cost and interpretive complexity that broader sequencing involves. For families navigating a diagnostic journey involving a suspected genetic condition, understanding what whole exome sequencing does and when it is most useful provides important context for the clinical conversations that follow.
What the Exome Is
The human genome contains approximately three billion base pairs of DNA, but only 1% to 2% of this code directly instructs cells to make proteins. This protein-coding region is known as the exome.
- High Diagnostic Yield: Despite representing a small fraction of total DNA, the exome harbors roughly 85% of all known disease-causing mutations.
- Clinical Interpretability: Functional impacts of exomic mutations (e.g., missense, nonsense, or frameshift variants) are far better characterized in medical literature than non-coding intergenic variants.
By sequencing all ~20,000 protein-coding genes simultaneously, a whole exome sequencing test captures an expansive molecular snapshot to pinpoint disease-causing genetic variants.
When a Whole Exome Sequencing Test Is Ordered
WES is typically indicated when:
- Targeted Testing Fails: Focused gene panels or chromosomal microarrays yield negative or inconclusive results.
- Genetically Heterogeneous Conditions: The clinical phenotype overlaps with multiple syndromes (e.g., global developmental delay or dysmorphic features).
- Atypical Presentations: A patient presents with a rare combination of symptoms that does not fit a single classical clinical diagnostic profile.
The whole exome sequencing test at Medgenome covers the full protein-coding genome with the depth and analytical rigor required for clinical diagnostic use rather than research-grade sequencing.
What the Test Produces and How Results Are Interpreted
A whole exome sequencing test produces a large volume of variant data that requires expert interpretation before it becomes a clinical result. Most variants identified are benign, common in the general population, and not associated with disease. The analytical process focuses on identifying variants that are rare, affect gene function in a way that is likely to cause disease, and are consistent with the inheritance pattern and clinical features of the patient being tested.
Variants are classified as pathogenic, likely pathogenic, of uncertain significance, likely benign, or benign. A pathogenic or likely pathogenic finding in a gene associated with the patient’s clinical presentation constitutes a diagnostic result. A variant of uncertain significance requires further evidence before it can be used as a definitive diagnosis.
The Benefit of Trio Analysis
When parental samples are available alongside the affected individual’s sample, sequencing all three together in what is called a trio analysis significantly improves the diagnostic yield. Comparing the variant identified in the child against the parents’ sequences allows the laboratory to determine whether the variant was inherited from an affected parent, inherited from an unaffected parent, or arose as a new mutation in the child. This additional information helps prioritize which variants are most likely to be causative.
The whole exome sequencing test offered through Medgenome includes the option for trio analysis and genetic counseling support, which makes the results more interpretable for families and clinicians working through a complex diagnostic process.
